KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Operating Leases (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Operating Leases for 3 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases changed 0.3% year-over-year to $8.9 million, compared with a TTM value of $8.9 million through Dec 2025, changed 0.3%, and an annual FY2025 reading of $8.9 million, changed 0.3% over the prior year.
  • Operating Leases was $8.9 million for Q4 2025 at Biocryst Pharmaceuticals, up from $8.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $12.2 million in Q3 2023 and bottomed at $8.1 million in Q3 2024.
  • Average Operating Leases over 3 years is $9.1 million, with a median of $8.7 million recorded in 2024.
  • Peak annual rise in Operating Leases hit 5.61% in 2024, while the deepest fall reached 34.15% in 2024.
  • Year by year, Operating Leases stood at $8.4 million in 2023, then rose by 5.61% to $8.9 million in 2024, then rose by 0.3% to $8.9 million in 2025.
  • Business Quant data shows Operating Leases for BCRX at $8.9 million in Q4 2025, $8.5 million in Q2 2025, and $8.9 million in Q4 2024.